Language Selector

    IMI Call 23 Partner Offer by Diagnostics Company

    Published on 21 July 2020
    Author: Nicole Wyss, National Contact Point Health

    An Israeli diagnostics company is interested in participating as partner and join a consortium under the Innovativer Medicines Initiative topic IMI-2020-23-03: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases.

    Carmel Diagnostics developed and validated novel non-invasive and minimally invasive assays that are based on the measurement of Oxidative Stress in blood, cerebrospinal fluid, tears and other biological fluids. Oxidative Stress plays a major role in the pathogenesis of Neurodegenerative diseases.

    They are interested in participating as partners in the topic IMI-2020-23-03: A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases.

    More information and contact details